Europe Breast Cancer Screening Market Forecast Report by Europe Breast Cancer Screening Market (Mammography Screening Market, MRI Screening Market, Ultrasound Screening Market) Countries (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands) and Company Analysis, 2024-2032

Growth Factors in the Europe Breast Cancer screening Industry

The Market expansion is driven by rising breast cancer incidence.

Because breast cancer is becoming more commonplace globally and more individuals are anticipated to require precise and efficient treatment alternatives, the European breast cancer market's compound annual growth rate (CAGR) is increasing. Since breast cancer is one of the most prevalent malignancies worldwide, more people are anticipated to receive diagnoses in the future as a result of improved diagnostics. The development of new technologies with state-of-the-art features for treatments and enhanced treatment efficacy is a key factor driving the market value growth.

Increased pharmaceutical developments, new product releases by significant industry players, better patient treatment outcomes, higher pharmacological efficacy and effectiveness, and recently developed therapeutics for the condition all contribute to the growth of the breast cancer market.

In addition, there has been a rise in the incidence of breast cancer among individuals due to factors such as decreased exercise, obesity, increased alcohol consumption, menopause, hormone issues, and family histories of cancer, as well as the government's increased support for the introduction of novel treatments and medications into the healthcare sector. Boost government advantages by creating more regulations, such reimbursement guidelines, to enable the general public to benefit from pricey medical procedures. As a result of the introduction of new laws and increased cost-effectiveness, the breast cancer market is driven by revenue growth.

The market is expanding in part because of the increasing number of clinical trials being conducted for the creation and assessment of screening tests.

Another factor fueling the market's expansion is the increase in clinical trials for the creation and assessment of screening tests. For example, a clinical trial supported by the University Medical Center, Utrecht, Netherlands, is anticipated to be finished by April 2023, according to clinicaltrials.gov. In this study, women aged 50-75 who exhibit higher than 75% mammographic density will have their biennial screening with mammography plus MRI compared to mammography alone, to see which is more cost-effective. Growing clinical trials are anticipated to provide market participants with a chance to develop cutting-edge screening tests, which will further propel the market's expansion.

Germany Breast Cancer screening Market Overview:

A significant share of the market is anticipated to be held by Germany because of things like the high incidence of breast cancer and growing awareness campaigns.

For example, in February 2022, the German startup Vara made breast cancer screening more accessible. In order to achieve its mission of giving every woman access to improved breast cancer screening that could save their lives, the firm has hired breast radiologists. Additionally, in October 2022, the Berlin-based startup Vara raised USD 4.8 million (EUR 4.5 million) in order to expand its goal of enabling universal access to data-driven breast cancer screening.

During the forecast period, awareness initiatives in the nation are also anticipated to hasten market expansion. For example, in October 2021, Wefra Life and the nonprofit organization Pink Ribbon Germany launched the "Breast Cancer Affects Us All" campaign to increase public awareness of breast cancer, foster a sense of community around the issue, and promote breast care. The campaign included a free multilingual app that covers all pertinent aspects of early breast cancer detection and prevention in a multimedia format in seven different languages. Throughout the projection term, these awareness campaigns are anticipated to boost the usefulness of breast cancer screening in the nation.

The country's market is expected to grow faster as a result of the increasing launches by industry participants. For example, in April 2021, FUJIFILM Europe GmbH announced the updated "Harmony" edition of the Amulet Innovality mammography system. The "Harmony" version, AWS V9.3, of the Fujifilm Amulet Innovative Mammography system was accessible.

Europe Breast Cancer screening Market Company Overview

Some of the industry leaders seen in the Europe Breast Cancer screening Market Includes AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc.

Europe Breast Cancer screening Market News

In January 2023, the government has allotted USD 12.2 million (GBP 10 million) to build 29 new breast cancer screening centers in order to expedite the identification and treatment of breast cancer, according to NHS England's Department of Health and Social Care.

In September 2022, to improve the collecting of cancer screening data throughout Europe, the European Union (EU) has provided funding for a new research project that the International Agency for Research on Cancer (IARC) has begun. The goal of the CanScreen-ECIS project is to enhance the caliber and reach of cancer screening initiatives throughout Europe by modernizing the current European Cancer Information System (ECIS).

Europe Breast Cancer Screening - Market breakup in 3 viewpoints:

1. Mammography Screening Market
2. MRI Screening Market
3. Ultrasound Screening Market

Countries – Market breakup in 3 viewpoints:

1. Breast Cancer Mammography Screening Population
2. Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
3. Breast Cancer Screening Market

• Mammography Screening Market
• Magnetic Resonance Imaging (MRI) Screening Market
• Ultrasound Screening Market

Country – Market breakup in 8 viewpoints:

• United Kingdom
• France
• Germany
• Italy
• Spain
• Switzerland
• Norway
• Netherlands

All the Key players have been covered from 5 Viewpoints:

1. Overviews
2. Key Person
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue

Company Analysis:

1. AstraZeneca
2. Novartis
3. Sanofi
4. Pfizer
5. Bayer AG
6. GlaxoSmithKline plc

Report Details: